Significance of p63 Amplification and Overexpression in Lung Cancer Development and Prognosis

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7113-7121

  Massion, Pierre P ^a,b,c   Taflan, Peter M ^a   Rahman, S M Jamshedur ^a   Yildiz, Pinar ^a   Shyr, Yu ^a   Edgerton, Mary E ^a,b   Westfall, Matthew D ^a   Roberts, John R ^a   Pietenpol, Jennifer A ^a   Carbone, David P ^a   Gonzalez, Adriana L ^a  

^a Department of Medicine ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME 3Q; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; DNA MICROARRAY; DYSPLASIA; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE COPY NUMBER; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MEMBRANE PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744221856     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gray, J. W., and Collins. C. Genome changes and gene expression in human solid tumors. Carcinogenesis (Lond.). 21: 443-452, 2000.
2. Massion, P. P., Kuo, W. L., Stokoe, D., Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., Albertson, D. G., Jablons, D. M., and Gray, J. W. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res., 62: 3636-3640, 2002.
3. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2: 305-316, 1998.
4. Dohn, M., Zhang, S., and Chen, X. p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene, 20: 3193-3205, 2001.
5. van Bokhoven, H., and McKeon, F. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol. Med., 8: 133-139, 2002.
6. Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., and Sidransky, D. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 97: 5462-5467, 2000.
7. Hagiwara, K., McMenamin, M. G., Miura, K., and Harris, C. C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res., 59: 4165-4169, 1999.
8. Patturajan, M., Nomoto, S., Sommer, M., Fomenkov, A., Hibi, K., Zangen, R., Poliak, N., Califano, J., Trink, B., Ratovitski, E., and Sidransky, D. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell. 1: 369-379, 2002.
9. Liefer, K. M., Koster, M. I., Wang, X. J., Yang, A., McKeon, F., and Roop, D. R. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res., 60: 4016-4020, 2000.
10. Westfall, M. D., Mays, D. J., Sniezek, J. C., and Pietenpol, J. A. The DNp63a phosphoprotein binds the p21 and 14-3-3S promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Weils syndrome-derived mutations. Mol. Biol. Cell. 23: 2264-2276, 2003.
11. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens [see comments], Nat. Med., 4: 844-847, 1998.
12. Deshmukh, P., Ramsey, L., and Garewal, H. S. Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling. Am. J. Clin. Pathol., 94: 192-195, 1990.
13. Camp, R. L., Charette, L. A., and Rimm, D. L. Validation of tissue microarray technology in breast carcinoma. Lab. Investig., 80: 1943-1949, 2000.
14. Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., and Miyake, M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene, 16: 2469-2477, 1998.
15. Fujita, T., Kiyama, M., Tomizawa, Y., Kohno, T., and Yokota, J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int. J. Oncol., 15: 927-934, 1999.
16. Stewart, Z. A., and Pietenpol, J. A. p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol., 14, 243-263, 2001.
17. Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V., Nowak, J. A., McIntire, D., Slamon, D., Gazdar, A., and Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 106: 377S-381S, 1994.
18. Little, N. A., and Jochemsen, A. G. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene, 20: 4576-4580, 2001.
19. Nylander, K., Coates, P. J., and Hall, P. A. Characterization of the expression pattern of p63 α and δ Np63 α in benign and malignant oral epithelial lesions. Int. J. Cancer, 87, 368-372, 2000.
20. Yamaguchi, K., Wu, L., Caballero, O. L., Hibi, K., Trink, B., Resto, V., Caims, P., Okami, K., Koch, W. M., Sidransky, D., and Jen, J. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int. J. Cancer, 86: 684-689, 2000.
21. Glickman, J. N., Yang, A., Shahsafaei, A., McKeon, F., and Odze, R. D. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum. Pathol., 32: 1157-1165, 2001.
22. Park, B. J., Lee. S. J., Kim, J. I., Lee, C. H., Chang, S. G., Park, J. H., and Chi, S. G. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res., 60: 3370-3374, 2000.
23. Heselmeyer, K., Schrock, E., du Manoir, S., Blegen, H., Shah, K., Steinbeck, R., Auer, G., and Ried, T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. USA, 93: 479-484, 1996.
24. Quade, B. J., Yang, A., Wang, Y., Sun, D., Park, J., Sheets, E. E., Cviko, A., Federschneider, J. M., Peters, R., McKeon, F. D., and Crum, C. P. Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol. Oncol., 80: 24-29, 2001.
25. Tannapfel, A., Schmelzer, S., Benicke, M., Klimpfinger, M., Kohlhaw, K., Mossner, J., Engeland, K., and Wittekind, C. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. J. Pathol., 195: 163-170, 2001.
26. Redon, R., Muller, D., Caulee, K., Wanherdrick, K., Abecassis, J., and du Manoir, S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: P1K3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res., 61: 4122-4129, 2001.
27. Sozzi, G., Pastorino, U., Moiraghi, L., Tagliabue, E., Pezzella, F., Ghirelli, C., Tomielli, S., Sard, L., Huebner, K., Pierotti, M. A., Croce, C. M., and Pilotti, S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res., 58: 5032-5037, 1998.
28. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. (Bethesda), 89: 857-862, 1997.
29. Hung, J., Kishimoto, Y., Sugio, K., Virmani, A., McIntire, D. D., Minna, J. D., and Gazdar, A. F. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J. Am. Med. Assoc., 273: 1908, 1995.
30. Todd, S., Franklin, W. A., Varella-Garcia, M., Kennedy, T., Hilliker, C. E., Jr., Hahner, L., Anderson, M., Wiest, J. S., Drabkin, H. A., and Gemmill, R. M. Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res., 57: 1344-1352, 1997.
31. Pelosi, G., Pasini, F., Olsen Stenholm, C., Pastorino, U., Maisonneuve, P., Sonzogni, A., Maffini, F., Pruneri, G., Fraggetta, F., Cavallon, A., Roz, E., Iannucci, A., Bresaola, E., and Viale, G. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J. Pathol., 198: 100-109, 2002.
32. Sniezek, J. C., Matheny, K. E., Burkey, B. B., Netterville, J. L., and Pietenpol, J. A. Expression of p63 and 14-3-3σ in normal and hyperdifferentiated mucosa of the upper aerodigestive tract. Otolaryngol. Head Neck Surg., 126: 598-601, 2002.
33. Bota, S., Auliac, J. B., Paris, C., Metayer, J., Sesboue, R., Nouvet, G., and Thiberville, L. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am. J. Respir. Crit. Care Med., 164: 1688-1693, 2001.
34. Bi, S., Lanza, F., and Goldman, J. M. The abnormal p53 proteins expressed in CML cell lines are non-functional. Leukemia (Baltimore), 7: 1840-1845, 1993.